** Shares of drug developer Xilio Therapeutics XLO.O more than double to $1.37 premarket
** AbbVie ABBV.N and XLO enters into collaboration and option agreement to develop cancer immunotherapies
** Under terms of the deal, XLO to receive $52 million in an upfront payment and will be eligible to receive up to about $2.1 billion in milestone payments
** Deal gives ABBV access to XLO's proprietary tumor-activation technology to develop new immunotherapies
** In the last 12 months, XLO has fallen 7%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。